DAMIAN, SILVIA
DAMIAN, SILVIA
Universita' degli Studi di MILANO
Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study
2022 P. Corradini, C. Agrati, G. Apolone, A. Mantovani, D. Giannarelli, V. Marasco, V. Bordoni, A. Sacchi, G. Matusali, C. Salvarani, P.L. Zinzani, R. Mantegazza, F. Tagliavini, M.T. Lupo-Stanghellini, F. Ciceri, S. Damian, A. Uccelli, D. Fenoglio, N. Silvestris, F. Baldanti, G. Piaggio, G. Ciliberto, A. Morrone, F. Locatelli, V. Sinno, M. Rescigno, M. Costantini
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples
2022 I. Capone, F. Bozzi, G.P. Dagrada, P. Verderio, E. Conca, A. Busico, M.A. Testi, V. Monti, M. Duca, C. Proto, S. Damian, A. Piccolo, F. Perrone, E. Tamborini, A. Devecchi, P. Collini, D. Lorenzini, A. Vingiani, L. Agnelli, G. Pruneri
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
2022 J. Azzollini, A. Vingiani, L. Agnelli, E. Tamborini, F. Perrone, E. Conca, I. Capone, A. Busico, B. Peissel, E. Rosina, M. Ducceschi, M. Mantiero, S. Lopez, F. Raspagliesi, M. Niger, M. Duca, S. Damian, C. Proto, F. de Braud, G. Pruneri, S. Manoukian
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
2021 F. Pietrantonio, S. Lonardi, F. Corti, G. Infante, M.E. Elez, M. Fakih, P. Jayachandran, A.T. Shah, M. Salati, E. Fenocchio, L. Salvatore, G. Curigliano, C. Cremolini, M. Ambrosini, J. Ros, R. Intini, F. Nappo, S. Damian, F. Morano, G. Fucà, M. Overman, R. Miceli
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study
2019 G. Mariani, G. Galli, S. Cavalieri, P. Valagussa, G. Bianchi, G. Capri, S. Cresta, L. Ferrari, S. Damian, M. Duca, F. de Braud, A. Moliterni
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
2017 A. Drilon, S. Siena, S.I. Ou, M. Patel, M.J. Ahn, J. Lee, T.M. Bauer, A.F. Farago, J.J. Wheler, S.V. Liu, R. Doebele, L. Giannetta, G. Cerea, G. Marrapese, M. Schirru, A. Amatu, K. Bencardino, L. Palmeri, A. Sartore-Bianchi, A. Vanzulli, S. Cresta, S. Damian, M. Duca, E. Ardini, G. Li, J. Christiansen, K. Kowalski, A.D. Johnson, R. Patel, D. Luo, E. Chow-Maneval, Z. Hornby, P.S. Multani, A.T. Shaw, F.G. De Braud
Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? : Analysis of a phase II trial
2013 S. Damian, L. Celio, E. De Benedictis, P. Mariani, F. Agustoni, F. Ricchini, F. De Braud